SNCA and Parkinson disease: Βsyn has been suggested to act neuroprotectively against alpha-synuclein pathology, inhibiting its binding to synaptic vesicle membranes, and inhibiting aggregation of alpha-synuclein in Parkinson’s disease [164,165].